We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Marcus A. Ray
Marcus A. Ray
Products
PRODUCTS
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Dennis Cantellops
,
Laurimer Kuilan-Torres
, and
Marcus A. Ray
Price:
$117.00
View
Xinxiang Tuoxin Pharmaceutical Co., Ltd.
Marcus A. Ray
Price:
$117.00
View
Qilu Antibotics Pharmaceutical Co., Ltd.
Marcus A. Ray
Price:
$117.00
View
Jiangsu Sihuan Bioengineering Pharmaceutical Co., Ltd.
Marcus A. Ray
Price:
$117.00
View
Icrom S.p.A
Philip F. Istafanos
and
Marcus A. Ray
Price:
$117.00
View
Nutravail, LLC
Kathleen Jordan
and
Marcus A. Ray
Price:
$117.00
View
Jubilant Cadista Pharmaceuticals, Inc.
Roseline N. Boateng
,
Marcia D. Fields
, and
Marcus A. Ray
Price:
$117.00
View
Zhejiang Raybow Pharmaceutical Co., Ltd.
Marcus A. Ray
Price:
$117.00
View
Actavis Italy SpA
Philip F. Istafanos
and
Marcus A. Ray
Price:
$117.00
View
lcrom S.p.A
Philip F. Istafanos
and
Marcus A. Ray
Price:
$117.00
View
View All Products by Marcus A. Ray
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
